Author of

• 34952

  +

  P05 - Early Stage/Localized Disease - Radiotherapy (ID 114)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Early Stage/Localized Disease
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 34956

    +

    P05.01 - Multicenter Retrospective Study of Stereotactic Body Radiotherapy in Non-Small Cell Lung Cancer in South Korea (KROG 17-09) (ID 2033)

    00:00 - 00:00  |  Presenting Author(s): Seung Gyu Park
    • Abstract
    • Slides

    Introduction
    

    Korean radiation oncology group conducted a multicenter retrospective study to evaluate the clinical outcomes of stereotactic body radiotherapy (SBRT) in patients with early stage non-small cell lung cancer (NSCLC) (KROG 17-09).

    Methods
    

    From 10 major academic centers, a total of 234 patients with newly diagnosed T1-2N0M0 NSCLC patients from 2005 to 2014 were included. Most were diagnosed pathologically (N=213, 91.0%). Seventeen patients (7.3%) were confirmed as N0 using pathologic mediastinal lymph node evaluation, while the others (92.7%) were confirmed as N0 radiologically. The patients who received additional surgery or systemic therapy were excluded. Various SBRT schedules were used in each center. The median radiation dose and fraction size were 60 Gy (range, 40-70 Gy) and 12 Gy (range, 5-20 Gy), respectively. The representative dose schedules are as follows; 60 Gy/4 fractions, 60 Gy/5 fractions, 48 Gy/4 fractions and 54 Gy/3 fractions in 67 (28.6%), 40 (17.1%), 31 (13.2%) and 16 (6.8%) patients, respectively. Disease failures were categorized as local, regional, and distant, defined as the evidence of progressive soft tissue abnormalities, any intrathoracic lymph node recurrence, and contralateral or extra-thoracic failure, respectively.

    Results
    

    The median age was 76.5 years (range, 44-91 years), and the majority were male (N=180, 76.9%). While 152 patients (65.0%) had an ECOG performance status of 0 to 1, 82 (35.0%) had an ECOG of 2 to 3, and 120 (51.3%) had underlying lung disease. The median tumor size was 25 mm (range, 7-58 mm), and 154 patients (65.8%) were T1 according to 7^th AJCC staging system. After the median follow-up of 28.5 months, 84 patients (35.9%) had disease failure; local failure in 39 (16.7%), regional failure in 27 (11.5%) and distant failure in 52 (22.2%). Among 39 local failures, 29 (12.4%) were in-field/marginal failures, and the other 10 (4.3%) were out-field failures at the same lobe. The 3-year primary tumor control, local control, regional control and distant control was 85.5%, 79.9%, 83.3% and 75.3%, respectively. The 3-year overall survival, cancer-specific survival and disease-free survival was 54.1%, 66.9% and 43.2%, respectively. Grade ≥3 treatment-related toxicities were reported in 16 patients (6.9%).

    Conclusion
    

    In this study, we were able to report the characteristics and clinical outcomes of SBRT in patients with early stage NSCLC in South Korea. We could confirm that the SBRT is a relatively safe and effective treatment modality. The results would be a meaningful reference to set future research directions.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.